Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab and Apatinib Combined With Chemotherapy (mFOLFOX6) in Neoadjuvant Therapy for Locally Advanced Colon Cancer

NCT04625803 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT04625803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04625803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab and Apatinib Combined With Chemotherapy (mFOLFOX6) in Neoadjuvant Therapy for Locally Advanced Colon Cancer
Lead sponsor
Zhejiang University
Phase
Phase 2
Overall status
Completed
Start date
January 4, 2021
Completion date
September 30, 2023
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, neoadjuvant therapy